AstraZeneca announces updated results from HIMALAYA Phase III trial of Imjudo

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi plus Imjudo demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localised treatment. These results from HIMALAYA will be presented today at the European Society for Medical Oncology, ESMO, Congress 2024 in Barcelona, Spain. At five years of follow-up, this latest exploratory analysis showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen, reduced the risk of death by 24% compared to sorafenib. An estimated 19.6% of patients treated with the STRIDE regimen were alive at five years versus 9.4% of those treated with sorafenib. In a subgroup analysis of patients in the trial who achieved disease control, defined as complete or partial response or stable disease, 28.7% of those treated with the STRIDE regimen were alive at five years versus 12.7% of patients treated with sorafenib. In addition, an exploratory analysis of depth of response showed that more patients treated with the STRIDE regimen experienced deep responses leading to longer survival compared to sorafenib.